Category survey

Molecular Mechanism of LRRK2 Biology and Pathology in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

High Throughput Screening to Discover Chemical Probes and Pharmacological Agents for Modulating Parkin Activity Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

TDP-43 acetylation as a pathogenic modification in ALS & related proteinopathies Investments > €500k United States of America Motor neurone diseases 2016    

Optimization of a novel series of thiazolopyridines for the treatment of SMA Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Toxicant-induced synaptic dysfunction and neurotoxicity in Parkinson disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Enhanced respiratory plasticity in models of respiratory motor neuron death Investments > €500k United States of America Motor neurone diseases 2016    

Novel mechanisms of actin dynamics underlying cell motility, axon growth, and ALS Investments > €500k United States of America Motor neurone diseases 2016    

Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Families At Risk: Long-term Impact of Huntingtons Presymptomatic Genetic Testi Investments > €500k United States of America Huntington’s disease 2016    

The Gut Microbiome in Neurodegenerative Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mechanisms and functions of subcellular motility Investments > €500k United States of America Motor neurone diseases 2016    

Membrane remodeling by alpha-synuclein: implications for function and disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mitochondrial DNA and Ape1 in Huntingtons Disease Investments > €500k United States of America Huntington’s disease 2016    

Optical imaging of small bio-molecules in living cells and tissues by nonlinear Raman microscopy coupled with vibrational tags Investments > €500k United States of America Huntington’s disease 2016    

NMR Based Studies of Alpha-Synuclein Aggregation and Inhibition Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Early detection of Huntingtons Disease: Longitudinal analysis of basal ganglia and cortical thickness Investments > €500k United States of America Huntington’s disease 2016    

Fbw7 as a therapeutic target for treating Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

CRCNS: Propagation of beta oscillations in cortico-basal ganglia-thalamic loop Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Development of a Telehealth Platform for Treatment with the SpeechVive Device Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Genomic profiling of pathological R-loop formation in human diseases. Investments > €500k United States of America Motor neurone diseases 2016    

Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mitochondrial DNA Quality Control and Neurodegeneration Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Function and mechanism of a novel SUMO protease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Genetic Analysis of the PINK1-Parkin Pathway Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Regulation of SNARE-dependent synaptic vesicle fusion Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Selectively inhibited transcription of mutant genes in neurodegenerative disease Investments > €500k United States of America Huntington’s disease 2016    

In vivo models of small RNP biogenesis and Spinal Muscular Atrophy Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Mechanistic analysis of axonal transport defects in neurodegenerative disease Investments > €500k United States of America Motor neurone diseases 2016    

Exploring the toxicity of aggregates associated with protein-misfolding diseases Investments > €500k United States of America Huntington’s disease|Motor neurone diseases 2016    

Targeting the Ubiquitin Proteasome System to Treat Spinal Muscular Atrophy Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Developing neuroprotective strategies for proteinopathy Investments > €500k United States of America Motor neurone diseases 2016    

Functions of alpha-Synuclein in Neurotransmitter Release Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Structure and Function of the Parkinsons disease associated protein LRRK2 Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Evaluation of glucocerebrosidase pathway biomarkers in Parkinson Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

The role of gut endocrine cells in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Combined Multi-Pinhole and Fan-Beam Brain SPECT Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

A Conserved Metalloprotease Required for Mitochondrial Maintenance and Protection Investments > €500k United States of America Motor neurone diseases 2016    

Influence of genotype on microglia phenotype and function in PD Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Development of SLIC, a methodology for synthetic lethal screening in the CNS Investments > €500k United States of America Huntington’s disease 2016    

The motor network in Parkinsons disease: mechanisms of therapy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Development of an information-rich assay for C9ORF72 as a test for ALS and FTD Investments > €500k United States of America Motor neurone diseases 2016    

Developing IMS-SID/MAD-MS Instrumentation for Characterizing Intrinsically Disordered Protein Structure Investments > €500k United States of America Huntington’s disease 2016    

Structural polymorphism in the misfolding and aggregation of expanded polyglutamine proteins Investments > €500k United States of America Huntington’s disease 2016    

Using naturally-occurring fungal prions as models of neurodegenerative protein misfolding Investments > €500k United States of America Neurodegenerative disease in general|Prion disease 2016    

Regulation of striatal acetylcholine transmission by cholinergic interneurons Investments > €500k United States of America Huntington’s disease 2016    

Modeling the effects of reducing huntingtin and Hdh alternative splicing in mice Investments > €500k United States of America Huntington’s disease 2016    

Chemical biological dissection of Ca2+ entry through Ca2+ channels Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Characterization of a complex regulatory element of Spinal Muscular Atrophy genes Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Re-Establishing Vascular Integrity in ALS via Endothelial Cell Transplant Investments > €500k United States of America Motor neurone diseases 2016    

Interactions between testosterone and oxidative stress in dopamine neurons Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016